Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CRN-04894 by Crinetics Pharmaceuticals for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome): Likelihood of Approval
CRN-04894 is under clinical development by Crinetics Pharmaceuticals and currently in Phase II for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). According...
Risk adjusted net present value: What is the current valuation of Crinetics Pharmaceuticals's CRN-04894?
CRN-04894 is a small molecule commercialized by Crinetics Pharmaceuticals, with a leading Phase II program in Pituitary ACTH Hypersecretion (Cushing...
CRN-04894 by Crinetics Pharmaceuticals for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome): Likelihood of Approval
CRN-04894 is under clinical development by Crinetics Pharmaceuticals and currently in Phase II for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). According...